west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "李秀钧" 5 results
  • Application of Evidence-Baqsed Medicine in Endocrine Disorders

    Release date:2016-09-07 02:28 Export PDF Favorites Scan
  • 二肽基肽酶Ⅳ抑制剂治疗糖尿病的研究现状

    Release date:2016-08-26 03:57 Export PDF Favorites Scan
  • Lipid-Modifying Therapy for Metabolic Syndrome: A Systematic Review

    Objective To assess the efficacy and safety of lipid-modifying agents for metabolism syndrome.Methods We searched The Cochrane Library, MEDLINE, EMbase, the China Biological Medicine Database, VIP and CMAC to 2007. We also did some handsearching and additional searching. Randomized controlled trials of lipidmodifying therapy for metabolic syndrome were included. Two reviewers independently extracted data from the eligible studies and evaluated the quality of the included studies. Meta-analyses were performed for the results of homogeneous studies using The Cochrane Collaboration’s RevMan 4.2.9 software. Results A total of 11 studies involving 1 422 patients with metabolic syndrome were included. The results indicated that there was no significant difference in TG between rosuvastatin and atorvastatin. However, rosuvastatin was more effective than atorvastatin on HDL-c improvement. Atorvastatin decreased TG levels greater than simvastatin, but simvastatin was superior to atorvastatin in HDL-c improvement. Two trials comparing fenofibrate with placebo were heterogeneous for some outcomes: one found no significant difference in improvements to HOMA-index, but the other trial indicated that fenofibrate was superior to placebo in improving QUICKI. However, the two trials revealed that fenofibrate favorably affected TG [WMD= – 1.77, 95%CI (– 2.21, – 1.33)] and HDL-c [WMD= 6.62, 95%CI (2.07, 11.17)] compared with placebo. No significant differences among atorvastatin, fenofibrate, alone or in combination, were observed in the proportion of metabolic syndrome reduction [RR=0.99, 95%CI (0.84, 1.16); RR=1.03, 95%CI (0.88, 1.20); RR=1.01, 95%CI (0.87, 1.18)]. Atorvastatin plus fenofibrate was superior to atorvastatin alone in TG and HDL-c improvement. Simvastatin-fenofibrate combination produced greater effectiveness in improving of HDL-c and TG compared with simvastatin alone. The fenofibrateorlistat combination was similar to fenofibrate in reducing metabolic syndrome [RR=1.15, 95%CI (0.68, 1.95)] and TG improvement, but was more effective than fenofibrate in HOMA-index improvement. This review of the clinical trials shows that the majority of lipid-modulating drugs did not have favorable effects on FPG, BP, BMI and WC. Six studies reported side effects, showing that the side effects for lipid-regulating drugs were mild to moderate, and well tolerated.Conclusion Our results suggest that lipid-regulating drugs in general exhibit beneficial effects on TG and HDL-c, but not on blood glucose and central obesity. The therapeutic effects of lipid-regulating drugs on blood pressure and insulin sensitivity are uncertain and have no positive effects on FPG, BMI and WC. There is insufficient evidence in this review to recommend the use of lipid-modifying drugs for metabolic syndrome due to low methodological quality, small ssamplesize and limited number of the trials. More high-quality and large-scale randomized controlled trials are required.

    Release date:2016-09-07 02:09 Export PDF Favorites Scan
  • 正常血糖-高胰岛素钳夹技术在胰岛素制剂药物代谢动力学研究中的应用进展

    正常血糖-高胰岛素钳夹技术是评价胰岛素敏感性的金标准技术。葡萄糖钳夹技术在糖尿病和胰岛素抵抗相关疾病的研究中具有独特的价值。近年来,随着胰岛素制剂及其类似物的迅速发展,该技术在其药物代谢动力学和药物效应动力学研究中的应用日益广泛。该文就正常血糖-高胰岛素钳夹技术在胰岛素制剂的药物代谢动力学及药物效应动力学研究中的发展历程和应用进展作一简要综述。

    Release date:2017-11-24 10:58 Export PDF Favorites Scan
  • 高原人群糖化血红蛋白的研究进展

    在多项血糖监测的指标中,糖化血红蛋白(hemoglobin A1c,HbA1c)目前是在评价血糖管理、治疗方案有效性及防控糖尿病并发症中运用最广泛且最重要的指标。然而高原低氧、低气压及民族等因素对 HbA1c 水平影响的结论仍存在争议,该文就高原环境及民族差异对 HbA1c 的具体影响及可能的机制进行了综述。

    Release date:2017-12-25 06:02 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content